CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Regardless of the degree of glycemic control, Linagliptin (LINA) has lower hypoglycemia risk than all doses of Glimepiride (GLIM), at all timeg points over a 2-year trial
DOI 10.1055/s-0034-1374983
Bibliografische Angaben
Nachweis in CareLit
Autor:innenB Gallwitz, J Rosenstock, S Patel, M von Eynatten, U Hehnke, L Mehlburger, KA Dugi, HJ Woerle
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe05/2014
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background, material and methods: Sulfonylurea (SU)-induced hypoglycemia is a common problem in type 2 diabetes. In a 2-year, randomized, double-blind study of the DPP-4 inhibitor LINA 5 mg/d (n = 764) vs. the SU GLIM 1 – 4 mg/d (n = 755) in patients uncontrolled by metformin, LINA provided noninferior reductions in HbA1c to GLIM with a lower hypoglycemia risk and no weight gain. This exploratory analysis evaluated…
Zitieren
Zitierempfehlung
B Gallwitz, J Rosenstock, S Patel, M von Eynatten, U Hehnke, L Mehlburger, KA Dugi, HJ Woerle (2014) Regardless of the degree of glycemic control, Linagliptin (LINA) has lower hypoglycemia risk than all doses of Glimepiride (GLIM), at all timeg points over a 2-year trial. Diabetologie und Stoffwechsel (05). https://doi.org/10.1055/s-0034-1374983
Mit CareLit weiterarbeiten